This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma

Trial Details

NCT ID
NCT07121946
Phase
PHASE1
Sponsor
LTZ Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • LTZ-301
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Buffalo, New York, United States|42.88645,-78.87837
  • New York, New York, United States|40.71427,-74.00597
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Age ≥ 18 years
  • Relapsed or refractory to at least 2 prior systemic treatment regimens
  • At least 1 bi-dimensionally measurable lesion (≥ 1.5 cm) in longest dimension
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →